Progress and problems with the use of viral vectors for gene therapy
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Gene therapy has a history of controversy. Encouraging results are starting to emerge from the clinic, but questions are still being asked about the safety of this new molecular medicine. With the development of a leukaemia-like syndrome in two of the small number of patients that have been cured of a disease by gene therapy, it is timely to contemplate how far this technology has come, and how far it still has to go.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In all cases of leukemia, the SCID X-1 correcting gene had inserted into the patient genome within or near tumor-promoting genes and caused transcriptional activation (Check, 2002; Kaiser, 2003; Thomas et al., 2003).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Thomas et al., 2003
Citations
Cites
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundA serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundHIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“AAV vector genomes flanked by AAV2 inverted terminal repeats (ITRs) have also been successfully cross-packaged in the capsids of alternative serotypes, creating a portfolio of pseudotypes with different specificitie”
BackgroundRubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J., Rooney, D. L., Zhang, M., Ihrig, M. M., McManus, M. T., et al. (2003) · Nature Genetics · doi:10.1038/ng1117 · Cited by 1,501
Naldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499 · cited 1×
“They have proven to be effective tools for gene delivery to the central nervous system (CNS), generating long-term gene expression in the absence of inflammatio”
BackgroundViral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M. A., Glorioso, J. C., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,342
Self-citationKordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251 · cited 1×
“gov/htbin-post/Omim/dispmim?168600">Parkinson disease”
Cited by
Items 301–400 of 1,002
Tzeng, S. Y., Hung, B. P., Grayson, W. L., & Green, J. J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.07.036 · Cited by 104
“While viral transduction can yield high efficiencies in genetic engineering of MSCs [5], viral vectors bring with them several safety concerns and limitations in the size and type of cargo they carry [6].”
Vector-mediated cancer gene therapy: An overview
Seth, P. K. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.5.1705 · Cited by 104
Dillon, C. P., Sandy, P., Nencioni, A., Kissler, S., Rubinson, D. A., & Parijs, L. V. (2004) · Annual Review of Physiology · doi:10.1146/annurev.physiol.67.040403.130716 · Cited by 104
Osborn, M. J., McElmurry, R. T., Lees, C. J., DeFeo, A. P., Chen, Z.-Y., Kay, M. A., Naldini, L., Freeman, G. J., Tolar, J., & Blazar, B. R. (2010) · Molecular Therapy · doi:10.1038/mt.2010.249 · Cited by 103
Self-citationLin, G., Revia, R. A., & Zhang, M. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202007096 · Cited by 103
Precise genome-editing in human diseases: mechanisms, strategies and applications
Zheng, Y., Li, Y., Zhou, K., Li, T., VanDusen, N. J., & Hua, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01750-2 · Cited by 106
“Nevertheless, infection with AdV and HSV-1 may trigger in fl ammatory reactions, 278 while AAV is considered to be both non-pathogenic and non-in fl ammatory.”
BackgroundExtension of the crRNA enhances Cpf1 gene editing in vitro and in vivo
Park, H. M., Liu, H., Wu, J., Chong, A., Mackley, V., Fellmann, C., Rao, A., Jiang, F., Chu, H., Murthy, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05641-3 · Cited by 102
Biodegradable microneedle patch for transdermal gene delivery
Qu, M., Kim, H., Zhou, X., Wang, C., Jiang, X., Zhu, J., Xue, Y., Tebon, P. J., Sarabi, S. A., Ahadian, S., et al. (2020) · Nanoscale · doi:10.1039/d0nr02759f · Cited by 102
Optimization and characterization of anionic lipoplexes for gene delivery
Srinivasan, C., & Burgess, D. J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.01.022 · Cited by 102
Measuring The Intravitreal Mobility of Nanomedicines with Single-Particle Tracking Microscopy
Martens, T. F., Vercauteren, D., Forier, K., Deschout, H., Remaut, K., Paesen, R., Ameloot, M., Engbersen, J. F., Demeester, J., De Smedt, S. C., et al. (2013) · Nanomedicine · doi:10.2217/nnm.12.202 · Cited by 94
Layek, B., & Singh, J. (2013) · Biomacromolecules · doi:10.1021/bm301720g · Cited by 101
Systemic Delivery of microRNA‐34a for Cancer Stem Cell Therapy
Shi, S., Han, L., Gong, T., Zhang, Z., & Sun, X. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201208077 · Cited by 100
Growth factors and growth factor gene therapies for treating chronic wounds
Mullin, J. A., Rahmani, E., Kiick, K. L., & Sullivan, M. O. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10642 · Cited by 102
“23,24 Nonviral approaches, on the other hand, offer a potentially promising combination of tunability and safety.”
BackgroundSelf-inactivating retroviral vectors with improved RNA processing
Kraunus, J., Schaumann, D., Meyer, J., Modlich, U., Fehse, B., Brandenburg, G., von Laer, D., Klump, H., Schambach, A., Bohne, J., et al. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302309 · Cited by 101
Tammam, S. N., Azzazy, H. M. E.-S., Breitinger, H., & Lamprecht, A. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00478 · Cited by 101
Functions of the adenovirus E4 proteins and their impact on viral vectors
Weitzman, M. (2005) · Frontiers in Bioscience · doi:10.2741/1604 · Cited by 81
Clinical development on the frontier: gene therapy for duchenne muscular dystrophy
Asher, D. R., Thapa, K., Dharia, S. D., Khan, N., Potter, R. A., Rodino‐Klapac, L. R., & Mendell, J. R. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1725469 · Cited by 100
Sharma, R., Lee, J.-S., Bettencourt, R. C., Xiao, C., Konieczny, S. F., & Won, Y.-Y. (2008) · Biomacromolecules · doi:10.1021/bm800876v · Cited by 94
The silent treatment: RNAi as a defense against virus infection in mammals
van Rij, R. P., & Andino, R. (2006) · Trends in biotechnology · doi:10.1016/j.tibtech.2006.02.006 · Cited by 99
Gene Therapy in Musculoskeletal Repair
Nixon, A. J., Goodrich, L. R., Scimeca, M. S., Witte, T. H., Schnabel, L. V., Watts, A. E., & Robbins, P. D. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.065 · Cited by 99
Cell Penetrating Peptide Conjugated Chitosan for Enhanced Delivery of Nucleic Acid
Layek, B., Lipp, L., & Singh, J. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226142 · Cited by 100
“Although most of the ongoing or approved gene therapy protocols use viral vectors for gene delivery, there is increasing interest in developing nonviral vectors to circumvent viral associated safety issues such as potential infectivity, immunogenicity, inflammation, and insertional mutagenesis [19–22].”
BackgroundImprovement of Biological Organisms Using Functional Material Shells
Liu, Z., Xu, X., & Tang, R. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201504480 · Cited by 99
Yang, R., Yang, X., Zhang, Z., Zhang, Y., Wang, S., Cai, Z., Jia, Y., Ma, Y., Zheng, C., Lu, Y., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302808 · Cited by 98
“Although viral gene delivery can effectively deliver siRNA, viral vectors can be immunogenic, or induce inflammation and potentially have oncogenic effects”
RetractedLong-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9
Stephens, C. J., Lauron, E. J., Kashentseva, E. A., Lu, Z. H., Yokoyama, W. M., & Curiel, D. T. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.02.009 · Cited by 98
“The cause of expression loss following adenoviral-mediated gene transfer is an area of intense study [39,50].”
Chen, Y., Zhou, L., Pang, Y., Huang, W., Qiu, F., Jiang, X., Zhu, X., Yan, D., & Chen, Q. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200010w · Cited by 98
Luo, L., Zhang, X., Hirano, Y., Tyagi, P., Barabás, P., Uehara, H., Miya, T. R., Singh, N., Archer, B. J., Qazi, Y., et al. (2013) · ACS Nano · doi:10.1021/nn305958y · Cited by 98
Tyner, K. M., Roberson, M. S., Berghorn, K. A., Li, L., Gilmour, R. F., Batt, C. A., & Giannelis, E. P. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.07.035 · Cited by 98
Newland, B., Zheng, Y. Q., Jin, Y., Abu-Rub, M., Cao, H., Wang, W., & Pandit, A. S. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2105575 · Cited by 98
Kolli, N., Lü, M., Maiti, P., Rossignol, J., & Dunbar, G. L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040754 · Cited by 99
Liu, H.-A., Liu, Y.-L., Ma, Z.-Z., Wang, J.-C., & Zhang, Q. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5891 · Cited by 97
Synthesis and Assembly of Click‐Nucleic‐Acid‐Containing PEG–PLGA Nanoparticles for DNA Delivery
Harguindey, A., Domaille, D. W., Fairbanks, B. D., Wagner, J., Bowman, C. N., & Cha, J. N. (2017) · Advanced Materials · doi:10.1002/adma.201700743 · Cited by 97
Polymersomes: A Synthetic Biological Approach to Encapsulation and Delivery
Massignani, M., Lomas, H., & Battaglia, G. (2010) · Advances in polymer science · doi:10.1007/12_2009_40 · Cited by 97
“cell plasma membrane [137–141].”
Magadala, P., & Amiji, M. M. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9065-0 · Cited by 97
Argyros, O., Wong, S. P., Niceta, M., Waddington, S. N., Howe, S. J., Coutelle, C., Miller, A. D., & Harbottle, R. P. (2008) · Gene Therapy · doi:10.1038/gt.2008.113 · Cited by 96
Schlottmann, F., Bucan, V., Vogt, P. M., & Krezdorn, N. (2021) · Medicina · doi:10.3390/medicina57030225 · Cited by 96
Enhanced Fluorescence Imaging of Live Cells by Effective Cytosolic Delivery of Probes
Massignani, M., Cantón, I., Sun, T. L., Hearnden, V. L., MacNeil, S., Blanazs, A., Armes, S. P., Lewis, A. L., & Battaglia, G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010459 · Cited by 96
“[19] and non-viral [20] transfection vectors, the expression of”
BackgroundTransfection of Difficult-to-Transfect Primary Mammalian Cells
Gresch, O., & Altrogge, L. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-352-3_5 · Cited by 96
Dual-purpose magnetic micelles for MRI and gene delivery
Wang, C., Ravi, S., Martinez, G. V., Chinnasamy, V., Raulji, P., Howell, M., Davis, Y., Mallela, J., Seehra, M. S., & Mohapatra, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.030 · Cited by 89
“Viral vectors offer highly efficient gene transfer, but unwanted immune stimulation and the potential for mutagenesis have virtually eliminated them from clinical trials [2,3].”
Ilovitsh, T., Feng, Y., Foiret, J. L., Kheirolomoom, A., Zhang, H., Ingham, E. S., Ilovitsh, A., Tumbale, S. K., Fite, B. Z., Wu, B., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914906117 · Cited by 95
Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications
Lopes, C., Cristóvão, J. S., Silvério, V., Lino, P. R., & Fonte, P. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2135502 · Cited by 95
“However, risks of immunogenicity, unwanted mutagenesis and cancer are still huge limitations of viral carriers [19].”
BackgroundGuo, J., Cheng, W. P., Gu, J., Ding, C., Qu, X., Yang, Z., & O’Driscoll, C. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.11.024 · Cited by 88
“Although viral vectors have shown potential, well documented safety issues limit their clinical application (Thomas et al., 2003).”
Magnetic nanoparticles: Applications in gene delivery and gene therapy
Majidi, S., Sehrig, F. Z., Samiei, M., Milani, M., Abbasi, E., Dadashzadeh, K., & Akbarzadeh, A. (2015) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2015.1014093 · Cited by 95
“A key hurdle to its clinical application is the deficiency of safe and operative delivery systems (Park et al. 2006, Thomas et al. 2003).”
BackgroundGonzalez‐Fernandez, T., Sathy, B. N., Hobbs, C. J., Cunniffe, G. M., McCarthy, H. O., Dunne, N., Nicolosi, V., O’Brien, F. J., & Kelly, D. J. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.03.044 · Cited by 95
Science and Bioethics of CRISPR-Cas9 Gene Editing: An Analysis Towards Separating Facts and Fiction.
Cribbs, A. P., & Perera, S. (2017) · Oxford University Research Archive (ORA) (University of Oxford) · Cited by 95
Interactions Between DNA and Gemini Surfactant: Impact on Gene Therapy: Part I
Ahmed, T., Kamel, A. O., & Wettig, S. D. (2016) · Nanomedicine · doi:10.2217/nnm.15.203 · Cited by 94
Gene Therapy for Regenerative Medicine
Hosseinkhani, H., Domb, A. J., Sharifzadeh, G., & Nahum, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030856 · Cited by 94
“Difficulty of immunogenicity [1], vector generation [2], carcinogenesis [3], restricted DNA packing capacity [4], and broad tropism [5] can severely eliminate their applications.”
BackgroundMicroRNAs as regulators of apoptosis mechanisms in cancer
Pileczki, V., Cojocneanu, R., Maralani, M., Berindan‐Neagoe, I., & Săndulescu, R. (2015) · Medicine and Pharmacy Reports · doi:10.15386/cjmed-512 · Cited by 94
“An effective method to deliver these therapeutic molecules is either the use of engineered viruses, or the use of nanoparticles [50, 51].”
MethodLi, Q., Xie, J., Li, R., Shi, J., Sun, J., Gu, R., Ding, L., Wang, L. Y., & Xu, B. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12242 · Cited by 94
“Lentiviral vectors can transduce non-dividing cells and ensure stable and long-term transgene expression compared to adenoviral vectors [40].”
BackgroundDiscovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs
Yang, M., & Mattes, J. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.08.004 · Cited by 94
Evans, B. C., Fletcher, R. B., Kilchrist, K. V., Dailing, E. A., Mukalel, A. J., Colazo, J. M., Oliver, M., Cheung-Flynn, J., Brophy, C. M., Tierney, J. W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12906-y · Cited by 84
Production of adenovirus vectors and their use as a delivery system for influenza vaccines
Vemula, S. V., & Mittal, S. K. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.519332 · Cited by 93
“8 10(13) Ad vector particles directly into the hepatic artery [128].”
BackgroundMalmo, J., Vårum, K. M., & Strand, S. P. (2011) · Biomacromolecules · doi:10.1021/bm1013525 · Cited by 92
On the delivery of small interfering RNAs into mammalian cells
Sioud, M. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2.4.639 · Cited by 92
“Effective delivery of siRNAs was also obtained with adenonovirus-associated viruses (AAVs), the only known mammalian virus that is capable of site-specific integration in human cells, thus minimising the chance of a mutagenic effect of the integrated virus [59].”
BackgroundInfluentialSustained Transgene Expression Using MAR Elements
Harraghy, N., Gaussin, A., & Mermod, N. (2008) · Current Gene Therapy · doi:10.2174/156652308786071032 · Cited by 92
“However, the use of viral vectors for gene therapy is not without concern (reviewed in [80]).”
BackgroundSynthesis and Gene Delivery of Poly(amido amine)s with Different Branched Architecture
Wang, R., Zhou, L., Zhou, Y., Li, G., Zhu, X., Gu, H., Jiang, X., Li, H., Wu, J., He, L., et al. (2010) · Biomacromolecules · doi:10.1021/bm901215s · Cited by 91
Virus-inspired nucleic acid delivery system: Linking virus and viral mimicry
Ni, R., Zhou, J., Hossain, N., & Chau, Y. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.07.005 · Cited by 91
RNAi: a novel antisense technology and its therapeutic potential.
Dallas, A., & Vlassov, A. V. (2006) · PubMed · Cited by 91
Targeted nonviral delivery of genome editors in vivo
Tsuchida, C. A., Wasko, K. M., Hamilton, J. R., & Doudna, J. A. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307796121 · Cited by 90
Prospects and implications of using chromatin insulators in gene therapy and transgenesis
Recillas‐Targa, F., Valadez‐Graham, V., & Farrell, C. M. (2004) · BioEssays · doi:10.1002/bies.20059 · Cited by 79
Rational design of cationic cyclooligosaccharides as efficient gene delivery systems
Díaz‐Moscoso, A., Balbuena, P., Gómez-García, M., Mellet, C. O., Benito, J. M., Gourriérec, L. L., Giorgio, C. D., Vierling, P., Mazzaglia, A., Micali, N. L., et al. (2008) · Chemical Communications · doi:10.1039/b718672j · Cited by 90
Yaguchi, M., Ohashi, Y., Tsubota, T., Sato, A., Koyano, K. W., Wang, N., & Miyashita, Y. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.238 · Cited by 89
“V iral vectors are promising tools for altering the expression of specific genes in the CNS to elucidate fundamental physiological mechanisms of the brain and to achieve therapeutic success (Davidson and Breakefield, 2003; Thomas et al. , 2003).”
Tailoring Charge Density and Hydrogen Bonding of Imidazolium Copolymers for Efficient Gene Delivery
Allen, M. H., Green, M., Getaneh, H. K., Miller, K. M., & Long, T. E. (2011) · Biomacromolecules · doi:10.1021/bm2003303 · Cited by 89
Talluri, T. R., Kumar, D., Glage, S., Garrels, W., Ivics, Z., Debowski, K., Behr, R., Niemann, H., & Kues, W. A. (2015) · Cellular Reprogramming · doi:10.1089/cell.2014.0080 · Cited by 89
“However, the drawbacks of virus-mediated reprogramming are manifold and include the potential immune response (Manno et al., 2006; Thomas et al., 2003), their expensive production (Grimm et al., 1998; Tiscornia et al., 2006), the preferential integration in 5¢-regions (UTRs) of genes that in turn…”
BackgroundInfluentialXiong, Z., Alves, C. S., Wang, J., Li, A., Liu, J., Shen, M., Rodrigues, J., Tomás, H., & Shi, X. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.09.005 · Cited by 88
α-Amino acid N-carboxyanhydride (NCA)-derived synthetic polypeptides for nucleic acids delivery
Liu, Y., & Yin, L. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.007 · Cited by 88
Safe and effective in vivo delivery of DNA and RNA using proteolipid vehicles
Brown, D. W., Wee, P., Bhandari, P., Bukhari, A. B., Grin, L., Vega, H., Hejazi, M., Sosnowski, D. L., Ablack, J., Clancy, E. K., et al. (2024) · Cell · doi:10.1016/j.cell.2024.07.023 · Cited by 88
“3,4 Although safer than many traditional viral vectors, host immunogenic responses against the AAV vector limit repeat dosing unless multiple AAV serotypes are employed.”
Efficient non-viral transfection of THP-1 cells
Schnoor, M., Buers, I., Sietmann, A., Brodde, M. F., Hofnagel, O., Robenek, H., & Lorkowski, S. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.03.014 · Cited by 88
“, 2004), but this approach is time-consuming, requires specially equipped laboratories with high security levels and may cause various unknown sideeffects (Thomas et al., 2003).”
BackgroundPolyethylenimine-mediated gene delivery to the lung and therapeutic applications
Conese, M. (2008) · Drug Design Development and Therapy · doi:10.2147/dddt.s2708 · Cited by 88
“…therapeutic genes into living cells, but their broad use is limited by the inability of repeated administration and the severe safety risks (Lehrman 1999; Liu and Muruve 2003), based upon their immunogenicity and their oncogenic potential (Thomas et al 2003; Cavazzana-Calvo and Fischer 2007).”
BackgroundNanoparticles for siRNA-Based Gene Silencing in Tumor Therapy
Babu, A., Muralidharan, R., Amreddy, N., Mehta, M., Munshi, A., & Ramesh, R. (2016) · IEEE Transactions on NanoBioscience · doi:10.1109/tnb.2016.2621730 · Cited by 88
“A decade ago, viral vectors were the most common gene delivery vehicles in cancer therapy [18], [19].”
BackgroundKizer, M. E., Deng, Y., Kang, G., Mikael, P. E., Wang, X., & Chung, A. J. (2019) · Lab on a Chip · doi:10.1039/c9lc00041k · Cited by 88
Polymer‐mediated gene therapy: Recent advances and merging of delivery techniques
Salameh, J. W., Zhou, L., Ward, S. M., Chalarca, C. F. S., Emrick, T. S., & Figueiredo, M. L. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1598 · Cited by 88
“Polyplexes prepared from branched PEI (obtained by ring-opening polymerization of aziridine) (Thomas et al., 2003) showed higher uptake than those from linear PEI (obtained by the hydrolysis of poly(2-oxazoline)); however, after endosomal escape, the polyplexes formed from linear PEI decomplex more easily than the bra…”
BackgroundHuang, B., Li, T., Alonso‐González, L., Gorre, R., Keatley, S. K., Green, A., Turner, P., Kallingappa, P. K., Verma, V., & Oback, B. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024501 · Cited by 88
“However, viral DNA may still trigger the immune system [59].”
BackgroundEfficient Delivery of Therapeutic miRNA Nanocapsules for Tumor Suppression
Liu, C., Wen, J., Meng, Y., Zhang, K., Zhu, J., Ren, Y., Qian, X., Yuan, X., Lu, Y., & Kang, C. (2015) · Advanced Materials · doi:10.1002/adma.201403387 · Cited by 85
CRISPR genome engineering and viral gene delivery: A case of mutual attraction
Schmidt, F., & Grimm, D. (2015) · Biotechnology Journal · doi:10.1002/biot.201400529 · Cited by 84
Majzoub, R. N., Ewert, K. K., & Safinya, C. R. (2016) · Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences · doi:10.1098/rsta.2015.0129 · Cited by 81
A Look to Future Directions in Gene Therapy Research for Monogenic Diseases
Porteus, M. H., Connelly, J. P., & Pruett‐Miller, S. M. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020133 · Cited by 87
“In the eyes of the public, general scientists, and practicing physicians this potential remains unrealized. While progress has not occurred as fast as anticipated, the strategy that Dr. Baltimore outlines remains one of the working paradigms in the field and would still be a “triumph of medicine.” This review briefly…”
BackgroundGene regulation with carbon-based siRNA conjugates for cancer therapy
Zhang, L., Zheng, W., Tang, R., Wang, N., Zhang, W., & Jiang, X. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.07.015 · Cited by 86
Wonder, E. A., Simón‐Gracia, L., Scodeller, P., Majzoub, R. N., Kotamraju, V. R., Ewert, K. K., Teesalu, T., & Safinya, C. R. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.052 · Cited by 86
Magnetic microgels and nanogels: Physical mechanisms and biomedical applications
Sung, B., Kim, M., & Abelmann, L. (2020) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10190 · Cited by 86
“147 For protein delivery, Lin et al. 148 reported a magnetic enzyme NG platform based on an Fe 3 O 4 core coated with a polyacrylamide gel network in which enzymes (lipase, peroxidase, trypsin, and cytochrome) were encapsulated.”
Highly Efficient Transfection of Human Primary T Lymphocytes Using Droplet-Enabled Mechanoporation
Joo, B., Hur, J., Kim, G.-B., Yun, S. G., & Chung, A. J. (2021) · ACS Nano · doi:10.1021/acsnano.0c10473 · Cited by 86
The role of the disulfide group in disulfide-based polymeric gene carriers
Lin, C., & Engbersen, J. F. J. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902878010 · Cited by 87
“However, the clinical application of viral carriers is associated with considerable safety concerns such as high cytotoxicity, insertional mutagenesis and undesirable immune response [5].”
BackgroundTherapeutic short hairpin RNA expression in the liver: viral targets and vectors
Grimm, D., & Kay, M. A. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302727 · Cited by 86
Self-citationSkin Electroporation of a Plasmid Encoding hCAP-18/LL-37 Host Defense Peptide Promotes Wound Healing
Steinstraesser, L., Lam, M. C., Jacobsen, F., Porporato, P. E., Chereddy, K. K., Becerikli, M., Stricker, I., Hancock, R. E. W., Lehnhardt, M., Sonveaux, P., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.258 · Cited by 86
Kalidasan, V., Ng, W. H., Ishola, O. A., Ravichantar, N., Tan, J. J., & Das, K. T. (2021) · Scientific Reports · doi:10.1038/s41598-021-98657-7 · Cited by 86
A Novel Listeria monocytogenes -Based DNA Delivery System for Cancer Gene Therapy
van Pijkeren, J. P., Morrissey, D., Monk, I. R., Cronin, M., Rajendran, S., O'Sullivan, G. C., Gahan, C. G. M., & Tangney, M. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.022 · Cited by 80
“Viral vector clinical trials have highlighted safety fears concerning vector integration (which has resulted in cases of leukemia) and fatal immune responses and have led to increased interest in nonviral systems (Thomas et al. , 2003; Yamamoto and Curiel, 2005).”
Identification of the murine firefly luciferase-specific CD8 T-cell epitopes
Limberis, M. P., Bell, C. L., & Wilson, J. M. (2009) · Gene Therapy · doi:10.1038/gt.2008.177 · Cited by 74
Bhang, S. H., Cho, S., Lim, J. M., Kang, J. M., Lee, T., Yang, H. S., Song, Y. S., Park, M. H., Kim, H.-S., Yoo, K., et al. (2009) · Stem Cells · doi:10.1002/stem.115 · Cited by 84
Harnessing nanoparticles for the efficient delivery of the CRISPR/Cas9 system
Rahimi, H., Salehiabar, M., Charmi, J., Barsbay, M., Ghaffarlou, M., Razlighi, M. R., Davaran, S., Khalilov, R. I., Sugiyama, M., Nosrati, H., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100895 · Cited by 84
Intelligent poly(l-histidine)-based nanovehicles for controlled drug delivery
Zhang, Y., Kim, I., Lu, Y., Xu, Y., Yu, D., & Song, W. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.005 · Cited by 85
Xu, W., Zhang, S., Qin, H., & Yao, K. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05957-3 · Cited by 84
Chen, H., Ma, X., Li, Z., Shi, Q., Zheng, W., Liu, Y., & Wang, P. (2012) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2011.12.005 · Cited by 84
“In this study, The SWNTs was modified by DSPE-PEG-Amino and Sulfo-LC-SPDP was used to mediate the conjugation of MDM2siRNA to f-SWNTs, and the gene therapy by f-SWNTs delivery has internal characteristics and superiorities compared to other drug delivery systems to a large extent [20,21].”
MethodThe Present and the Future of Degradable Dendrimers and Derivatives in Theranostics
Leiro, V., Garcia, J. P., Tomás, H., & Pêgo, A. P. (2015) · Bioconjugate Chemistry · doi:10.1021/bc5006224 · Cited by 84
RNA interference: Implications for cancer treatment
Masiero, M., Nardo, G., Indraccolo, S., & Favaro, E. (2007) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.12.004 · Cited by 84
“Adeno and adeno-associated derived viral vectors are both able to infect dividing and non-dividing cells, but only the adeno-associated derived vectors have the ability to integrate in a site-specific manner avoiding the risk of insertional mutation known for retro- and lentiviral derived vectors (Amalfitano, 2003, 20…”
BackgroundYou, X., Gu, Z., Huang, J. C., Kang, Y., Chu, C., & Wu, J. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.05.040 · Cited by 84
Electrostatic surface modifications to improve gene delivery
Shmueli, R. B., Anderson, D. G., & Green, J. J. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425241003603653 · Cited by 83
“However, there are continuing safety concerns with their use, such as the potential for tumor induction [29] and the generation of immune responses [30].”
BackgroundNanotherapeutic systems for local treatment of brain tumors
Chakroun, R. W., Zhang, P., Lin, R., Schiapparelli, P., Quinones‐Hinojosa, A., & Cui, H. (2018) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1479 · Cited by 70
Nanomaterials for mRNA ‐based therapeutics: Challenges and opportunities
Li, D., Liu, Q., Yang, M., Xu, H., Zhu, M., Zhang, Y., Xu, J., Tian, C., Yao, J., Wang, L., et al. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10492 · Cited by 82
“However, viral vectors have disadvantages of potential carcinogenic, high immunogenic, limited gene packaging ability, and low-volume production.(25,26) Mechanical transfection, such as injec-”
BackgroundMiyagawa, Y., Marino, P., Verlengia, G., Uchida, H., Goins, W. F., Yokota, S., Geller, D. A., Yoshida, O., Mester, J., Cohen, J. B., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423556112 · Cited by 80
“blastoma gene family deregulates G(1) control causing immortalization and increased”
BackgroundGene therapy in clinical medicine
Selkirk, S. M. (2004) · Postgraduate Medical Journal · doi:10.1136/pgmj.2003.017764 · Cited by 84
Memory in aged mice is rescued by enhanced expression of the GluN2B subunit of the NMDA receptor
Brim, B. L., Haskell, R., Awedikian, R., Ellinwood, N. M., Jin, L., Kumar, A., Foster, T. C., & Magnusson, K. R. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.10.026 · Cited by 73
Metadata
- Authors
- Thomas, C. E., Ehrhardt, A., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature Reviews Genetics
- Published
- 2003-05-01
- Volume
- 4
- Issue
- 5
- Pages
- 346-358
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2014356856
- Cited by
- 2,501
- References
- 124
- Citations by year
- 2026: 41 · 2025: 59 · 2024: 110 · 2023: 98 · 2022: 109 · 2021: 116 · 2020: 151 · 2019: 153 · 2018: 150 · 2017: 168 · 2016: 142 · 2015: 143 · 2014: 148 · 2013: 122 · 2012: 109
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- Hospital for Sick Children
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- gene therapy, viral vectors, clinical gene therapy, gene therapy safety, retroviral vectors, clinical trials
- MeSH terms
- Dependovirus, Adenoviridae, Defective Viruses, Genetic Vectors, Humans, Neoplasms, Retroviridae, Viruses, Genetic Therapy, Lentivirus, Simplexvirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.